Timing correction: Biogen reports today, Wednesday, July 29, 2026, before the U.S. market opens, with its earnings call at 8:30 a.m. ET—not tomorrow. (investors.biogen.com)
BIIB’s Q2 report is unusually important because it is the first quarter to include the completed acquisition of Apellis. The central question is no longer simply whether the legacy business met quarterly expectations; it is whether management can provide a credible, consolidated 2026 outlook that demonstrates how SYFOVRE and EMPAVELI change Biogen’s top-line trajectory, earnings power, cash generation, and leverage profile.
Reported EPS will be a noisy measure of execution. On July 1, Biogen pre-announced approximately $164 million of acquired IPR&D, upfront, and milestone expense for Q2—equivalent to roughly $0.95 per diluted share on both a GAAP and non-GAAP basis. It also flagged a potential $290–$320 million Q3 IPR&D/upfront/milestone expense, or $1.75–$1.95 per share. Investors should therefore focus on underlying revenue, updated full-year guidance, Apellis contribution and integration costs, and cash-flow/deleveraging commentary rather than the headline EPS comparison alone. (sec.gov)
Apellis closed on May 14, so Q2 should include roughly half a quarter of contribution from SYFOVRE and EMPAVELI, plus acquisition accounting, integration spending, and additional interest expense. The acquired products generated $689 million in 2025 net product revenue, and Biogen had characterized their combined growth outlook as mid- to high-teens through at least 2028. Management has said the deal should become accretive to non-GAAP EPS in 2027 and materially improve the company’s longer-term EPS growth rate. (investors.biogen.com)
What investors need from management:
New 2026 revenue and non-GAAP EPS guidance inclusive of Apellis.
Biogen’s prior standalone framework called for 2026 revenue to decline by a mid-single-digit percentage and non-GAAP EPS of $14.25–$15.25, excluding Apellis. The prior EPS range already incorporated about $1.00 of Q1/Q2 IPR&D charges, but the newly pre-announced Q2 charge is somewhat larger than the $0.80 Q2 charge assumed in April. The updated guide needs to bridge: legacy operating performance, Apellis revenue, purchase-accounting effects, incremental interest expense, integration costs, and the revised IPR&D burden. (sec.gov)
SYFOVRE’s commercial trajectory.
This is likely the biggest debate within the acquisition. Investors will want prescription/injection trends, patient growth, persistence, competitive positioning, commercial investment plans, and any update on a prefilled-syringe filing. A credible plan to improve patient and physician activation in geographic atrophy is more important than a one-quarter revenue beat.
EMPAVELI and the nephrology franchise.
EMPAVELI is strategically valuable beyond near-term sales: it brings nephrology commercial infrastructure ahead of potential felzartamab launches. Management has targeted the first Phase 3 readout in antibody-mediated rejection in kidney-transplant patients for the first half of 2027. Commentary on the pace of the C3G/IC-MPGN launch, the field-force integration, and felzartamab launch readiness should matter. (investors.biogen.com)
Q1 established a solid, though not entirely clean, baseline: total revenue was $2.48 billion, up 2% year over year, and non-GAAP EPS was $3.57. However, constant-currency total revenue declined 2%, and several categories carried timing or inventory effects. (sec.gov)
| Q1 2026 operating datapoint | Why it matters for Q2 |
|---|---|
| LEQEMBI global in-market sales: $168M, +74% YoY | The major organic growth lever; look for continued demand, U.S. patient growth, and the impact of simplifying access and treatment. |
| SKYCLARYS revenue: $151M, +22% YoY | Demand and ex-U.S. launch momentum matter more than quarterly inventory movement. |
| ZURZUVAE revenue: $55M, +100% YoY | Still small, but an important proof point for the growth portfolio. |
| SPINRAZA revenue: $374M, -12% YoY | Shipment timing distorted Q1; high-dose conversion and franchise durability are key. |
| MS product revenue: $958M, flat reported / -3% constant currency | The mature portfolio remains the principal drag, especially after Q1’s TYSABRI timing benefit. |
Source: Biogen’s Q1 results. (sec.gov)
Two items warrant particular caution when assessing Q2 quality:
The FDA approved LEQEMBI IQLIK as a once-weekly subcutaneous initiation dose on July 13, with U.S. availability expected in late August. This means the approval itself is no longer an earnings-day catalyst. Instead, investors should focus on management’s expectations for launch timing, physician uptake, patient access, and whether at-home initiation can meaningfully improve the treatment funnel and persistence. (investors.biogen.com)
The bigger new pipeline question is diranersen (BIIB080). Phase 2 CELIA data showed tau biomarker reduction and cognitive signals, and Biogen plans to advance the program to Phase 3. However, CELIA did not meet its primary dose-response endpoint on CDR-SB; the 60 mg dose showed the strongest result, with 26% slowing on CDR-SB versus placebo at 18 months. On the call, investors should seek the Phase 3 design, dose selection, timing, cost, regulatory strategy, and how management interprets the lack of a higher-dose response. (investors.biogen.com)
Biogen has also added pipeline momentum in 2026: salanersen received FDA Breakthrough Therapy Designation for SMA, while the company agreed to acquire RayThera for up to $1 billion, predominantly contingent on future clinical and regulatory milestones. These developments reinforce the strategy of reinvesting in neuroscience, immunology, and rare disease—but they also reinforce why investors should expect earnings volatility from business-development charges and higher R&D spending. (investors.biogen.com)
BIIB enters Q2 as a transformed story: a mature neurology franchise with improving growth products, now supplemented by Apellis’ retinal and nephrology assets and a more credible late-stage pipeline. The report’s real test is whether management can convert that strategic narrative into an investable financial framework—one that shows revenue growth resuming, EPS accretion beginning in 2027, and debt being repaid without sacrificing pipeline investment. The pre-announced Q2 charge makes the headline EPS result largely secondary; the updated full-year guide and Apellis KPI disclosure will determine the market’s reaction.